Tofacitinib for Prurigo Nodularis: A Case Report

PURPOSE: Despite recent advances in the treatment of prurigo nodularis, conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of Prurigo nodularis has rarely been explored. PATIENTS AND METHODS: We present a case of prurigo...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Changlan, Li, Chunxiao, Zhou, Yingying, Wang, Qiuyue, Xie, Ping, Li, Tianhao, Hao, Pingsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956247/
https://www.ncbi.nlm.nih.gov/pubmed/35340735
http://dx.doi.org/10.2147/CCID.S354025
_version_ 1784676523982192640
author Peng, Changlan
Li, Chunxiao
Zhou, Yingying
Wang, Qiuyue
Xie, Ping
Li, Tianhao
Hao, Pingsheng
author_facet Peng, Changlan
Li, Chunxiao
Zhou, Yingying
Wang, Qiuyue
Xie, Ping
Li, Tianhao
Hao, Pingsheng
author_sort Peng, Changlan
collection PubMed
description PURPOSE: Despite recent advances in the treatment of prurigo nodularis, conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of Prurigo nodularis has rarely been explored. PATIENTS AND METHODS: We present a case of prurigo nodularis successfully treated with, JAK inhibitor tofacitinib with no adverse effects. RESULTS: This case report of successful treatment shows a good clinical efficacy of using JAK inhibitor tofacitinib in the treatment of prurigo nodularis. Cytokines may be an important cause of prurigo nodularis. CONCLUSION: JAK inhibitor tofacitinib may be a new option for the treatment of prurigo nodularis, especially for patients who have failed conventional treatment.
format Online
Article
Text
id pubmed-8956247
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-89562472022-03-26 Tofacitinib for Prurigo Nodularis: A Case Report Peng, Changlan Li, Chunxiao Zhou, Yingying Wang, Qiuyue Xie, Ping Li, Tianhao Hao, Pingsheng Clin Cosmet Investig Dermatol Case Report PURPOSE: Despite recent advances in the treatment of prurigo nodularis, conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of Prurigo nodularis has rarely been explored. PATIENTS AND METHODS: We present a case of prurigo nodularis successfully treated with, JAK inhibitor tofacitinib with no adverse effects. RESULTS: This case report of successful treatment shows a good clinical efficacy of using JAK inhibitor tofacitinib in the treatment of prurigo nodularis. Cytokines may be an important cause of prurigo nodularis. CONCLUSION: JAK inhibitor tofacitinib may be a new option for the treatment of prurigo nodularis, especially for patients who have failed conventional treatment. Dove 2022-03-21 /pmc/articles/PMC8956247/ /pubmed/35340735 http://dx.doi.org/10.2147/CCID.S354025 Text en © 2022 Peng et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Peng, Changlan
Li, Chunxiao
Zhou, Yingying
Wang, Qiuyue
Xie, Ping
Li, Tianhao
Hao, Pingsheng
Tofacitinib for Prurigo Nodularis: A Case Report
title Tofacitinib for Prurigo Nodularis: A Case Report
title_full Tofacitinib for Prurigo Nodularis: A Case Report
title_fullStr Tofacitinib for Prurigo Nodularis: A Case Report
title_full_unstemmed Tofacitinib for Prurigo Nodularis: A Case Report
title_short Tofacitinib for Prurigo Nodularis: A Case Report
title_sort tofacitinib for prurigo nodularis: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956247/
https://www.ncbi.nlm.nih.gov/pubmed/35340735
http://dx.doi.org/10.2147/CCID.S354025
work_keys_str_mv AT pengchanglan tofacitinibforprurigonodularisacasereport
AT lichunxiao tofacitinibforprurigonodularisacasereport
AT zhouyingying tofacitinibforprurigonodularisacasereport
AT wangqiuyue tofacitinibforprurigonodularisacasereport
AT xieping tofacitinibforprurigonodularisacasereport
AT litianhao tofacitinibforprurigonodularisacasereport
AT haopingsheng tofacitinibforprurigonodularisacasereport

Ejemplares similares